Oct 21, 2023 / 01:00PM GMT
Operator
Good afternoon, and thank you all for joining the ORIC Pharmaceuticals Business Update ESMO 2023 Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I'd now like to turn the call over to ORIC's CFO, Dominic Piscitelli. Please go ahead.
Dominic G. Piscitelli - ORIC Pharmaceuticals, Inc. - CFO
Good afternoon, and welcome to the ORIC Pharmaceuticals ESMO 2023 Conference Call. Earlier today, we issued a press release highlighting initial clinical data from our Phase Ib trial of ORIC-114 in EGFR and HER2-mutated cancers. You may find the press release posted on the Investor page of oricpharma.com. We have prerecorded our prepared remarks, after which we will host a live Q&A session.
Before we begin, starting on Slide 2, during this conference call, we will be making forward-looking statements, including forward-looking statements based on our current expectations and projections about future events and trends that may affect our business, utilizing data available to us as of September 26, 2023.
Oric Pharmaceuticals Inc Business Update ESMO Call Transcript
Mar 01, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers